Introduction to the Altimmune Class Action Lawsuit
The Altimmune class action lawsuit seeks to represent purchasers or acquirers of Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025, inclusive (the “Class Period”). Captioned Collier v. Altimmune, Inc., No. 25-cv-02581 (D. Md.), the Altimmune class action lawsuit charges Altimmune and certain of Altimmune’s top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Altimmune class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com.
Lead plaintiff motions for the Altimmune class action lawsuit must be filed with the court no later than October 6, 2025.
Allegations in the Altimmune Class Action Lawsuit
Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity, metabolic, and liver diseases.
The Altimmune class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Defendants created the false impression that they possessed reliable information pertaining to the results of Altimmune’s IMPACT Phase 2b metabolic associated steatohepatitis (“MASH”) trial;
- Altimmune failed to meet an important statistical significance marker relating to the fibrosis reduction primary endpoint; and
- Altimmune concealed higher responses in the placebo group, which defendants knew or should have known would negatively impact the IMPACT Phase 2b MASH trial’s topline results.
The Altimmune class action lawsuit further alleges that on June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH and disclosed that “[a]lthough we saw positive trends in fibrosis improvement, statistical significant was not achieved on this endpoint.” On this news, the price of Altimmune stock fell more than 53%, according to the complaint.
The Lead Plaintiff Deadline in the Altimmune Class Action Lawsuit
Lead plaintiff motions for the Altimmune class action lawsuit must be filed with the court no later than October 6, 2025. When a securities class action is filed:
- The person who files the first complaint is required to publish a notice announcing the filing.
- Anyone who wants to be the lead plaintiff on behalf of the class must thereafter file a motion to be appointed as lead plaintiff(s) no later than 60 days after the notice was published.
The Eligibility Criteria for Lead Plaintiff Appointment in the Altimmune Class Action Lawsuit
To be eligible for appointment as the lead plaintiff in the Altimmune Class Action Lawsuit, an investor must meet the following criteria:
- Securities Acquisition: The investor must have purchased or acquired Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025.
- Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by Altimmune and its executives.
- Typicality and Adequacy: The investor’s legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.
It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the class action lawsuit, as courts have consistently recognized the rights of non-U.S. investors in securities class actions.
Options for Investors
Investors facing losses due to the Altimmune class action lawsuit have several options available to them. Each option carries its own implications and potential outcomes.
Joining the Class Action
One of the most straightforward options for investors is to join the Altimmune class action lawsuit . By doing so, they can collectively pursue compensation for their losses without the need for individual litigation.
Filing an Individual Claim
In certain situations, investors may opt to file individual claims instead of joining the Altimmune lawsuit. This option may be appropriate for those who believe their losses are significant enough to warrant separate legal action.
Seeking Legal Advice
Consulting with a legal professional experienced in securities law can provide investors with insights into their best course of action. Legal experts can help assess the merits of individual claims versus joining the class action.
The Role of Law Firms
Law firms play a crucial role in the Altimmune class action lawsuit. They provide the necessary legal experience and representation for investors seeking to recover their losses.
Selecting a Law Firm
Investors have the option to choose a law firm that practices securities fraud cases. A reputable firm can offer valuable insights and increase the likelihood of a favorable outcome. If you suffered substantial losses and wish to serve as lead plaintiff of the Altimmune class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com.
Contact Timothy L. Miles Today About an Altimmune Class Action Lawsuit
If you suffered substantial losses and wish to serve as lead plaintiff of the Altimmune class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com. (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: tmiles@timmileslaw.com
Website: www.classactionlawyertn.com
